Skip to content

The effect of clonidine on pain post-tonsillectomy in children

A randomised controlled trial investigating the efficacy of Clonidine to help improve the management of pain post-tonsillectomy in children (CHIMP)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621001606875
Acronym
CHIMP
Enrollment
190
Registered
2021-11-25
Start date
2022-02-16
Completion date
2025-12-31
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Tonsillectomy is one of the most common childhood surgical procedures, however the postoperative recovery is often long and challenging for children and their families.. This study aims to investigate if seven days of oral clonidine is able to improve pain management in children post-tonsillectomy, without increasing the risk of postoperative complications when compared to placebo. Hypothesis: clonidine will significantly decrease postoperative parental reported pain scores following tonsillectomy.

Interventions

The study will be a randomized, double-blinded and placebo-controlled study. Following approval from the treating anaesthetist and voluntary written informed consent by the parent/guardian, the recruited children will be block randomised and assigned to one of the two groups, in a 1:1 ratio to receive either clonidine (10mcg/ml) suspension or placebo suspension.The blinding of the drug will be performed by the Clinical Trials Pharmacy who will provide us with the unblinding folders/envelopes fo

The study will be a randomized, double-blinded and placebo-controlled study. Following approval from the treating anaesthetist and voluntary written informed consent by the parent/guardian, the recruited children will be block randomised and assigned to one of the two groups, in a 1:1 ratio to receive either clonidine (10mcg/ml) suspension or placebo suspension.The blinding of the drug will be performed by the Clinical Trials Pharmacy who will provide us with the unblinding folders/envelopes for the study. Participants, research assistants, nurses and doctors will be blinded to the allocation. Patients will receive 3mcg/kg (max 150 mcg) of their assigned suspension (rounded to the nearest 0.1 ml) for their first perioperative dose, 30-45 minutes prior to surgery induction. Subsequently, on days 0, 1, 2, 3, 4 and 5 they will receive 1 mcg/kg (0.1 ml/kg, max 50mcg) of their assigned suspension in the morning and at 2pm by mouth, and 2mcg/kg (0.2 ml/kg, max 100 mcg) at night by mouth. Then on days 6 and 7 they will receive 0.5mcg/kg (0.05ml/kg) in the morning and 1mcg/kg (0.1ml/kg) at night. Participants will receive enough doses day 0 (day of surgery) – day 7. The study medications are in addition to the standard medications normally prescribed post tonsillectomy.In the absence of allergies or adverse drug reactions or contraindication, all patients will be prescribed a weight-based regimen of QID paracetamol (15mg/kg) and TDS ibuprofen (10mg/kg) for 7 days postoperatively. Oxycodone (6-hourly PRN) will be also prescribed to all patients. All patients will be given a ‘test dose’ of oxycodone while in hospital to demonstrate its safety to parents and asses patient tolerance. Children without additional risk factors for opioid-related complications will receive oxycodone at 0.1mg/kg of ideal body weight according to our institutional guidelines. Ten-to fifteen doses of oxycodone (1mg/ml syrup) will be dispensed on discharge (up to maximum of 50mls) if patients maintain their oxygen saturation >92% on room air and without excessive sedation following the test dose. The clinical team on review of test dosing may then decide to use a lower oxycodone dose of 0.05mg/kg or avoid this entirely. Four ondansetron 4mg wafers will also be dispensed for use on the first two mornings and then as required as per usual discharge protocol. The patient receiving clonidine/placebo will have tolerated it for at least 3 doses in hospital prior to discharge without any adverse event attributable to the medication being observed. There will be active follow up with the families to ensure study adherence. All families are provided with a standard diary to document medication administration following tonsillectomy surgery. Our families will also be provided with a study diary where they will document further information. They will also report this in the study database via survey links sent daily. After the recruitment of the first 50 patients there will be a review of the postoperative CO2 and Spo2, mean heart rates and mean blood pressure during the first postoperative night.

Sponsors

Perth Children's Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
4 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

Children aged 4 – 16 years Undergoing elective surgery under general anaesthesia for tonsillectomy +/- adenoidectomy +/- grommets or cautery of inferior turbinates Staying overnight in hospital

Exclusion criteria

Known cerebrovascular disease, heart failure, occlusive peripheral vascular disorders, such as Raynaud’s disease, cardiac arrhythmias Known cardiovascular, respiratory or neurological disorders giving an ASA III or above status Known hypersensitivity to the active substance or to any of the excipients listed Language barriers impeding data collection Department for Child Protection and Family Support is involved in their care Planned admissions to the Paediatric Intensive Care Unit (PICU)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026